Results of ADAGIO study with Azilect® in Parkinson's disease published in The New England Journal of Medicine

One of the largest Parkinson's disease studies demonstrates benefit
of early treatment with Azilect® 1 mg/day

H. Lundbeck A/S' (Lundbeck) partner Teva Phamaceuticals Industries
Ltd. (Teva) today announced that results from the ADAGIO trial,
published online today in The New England Journal of Medicine,
demonstrated that Parkinson's disease patients receiving Azilect®
(rasagiline) 1mg/day at the start of the study (early-start group)
experienced superior benefit over 18 months compared with those who
started the exact same treatment nine months later (delayed-start
group)1. This finding is consistent with a possible disease-modifying
effect for Azilect®  1 mg/day.

Professor C. Warren Olanow, MD, Department of Neurology, Mount Sinai
School of Medicine, New York and co-principal investigator of the
ADAGIO study, commented, "A therapy that slows or stops disease
progression is the greatest unmet need in the treatment of patients
with Parkinson's disease. Current therapies do not prevent the
development of disability in such patients. The results of the ADAGIO
study provide support for the possibility that early treatment with
Azilect® 1 mg/day may slow the development of disability."

Azilect® is the first Parkinson's disease treatment to succeed in a
prospective delayed-start study, a trial design specifically
developed to test for the possibility of a disease-modifying effect.

Professor Olivier Rascol, Department of Clinical Pharmacology,
University Hospital, Toulouse, France and ADAGIO co-principal
investigator, stated, "The results of the ADAGIO study provide novel
data to support the use of Azilect® 1 mg daily as initial treatment
of patients with Parkinson's disease. The ADAGIO study, which
utilized a novel trial design with three primary endpoints, suggests
that the drug has a positive impact on slowing the progression of
patients' disability, beyond its already known symptomatic benefit."

The content of this release will have no influence on the Lundbeck
Group's financial result for 2009.

About ADAGIO
ADAGIO (Attenuation of Disease progression with Azilect® Given
Once-daily) was a randomized, multi-center, double-blind,
placebo-controlled, parallel-group study prospectively examining
rasagiline's potential disease-modifying effects in 1,176 patients
with early, untreated Parkinson's disease. Patients from 129 centers
in 14 countries participated and were randomized to initiate
treatment for 72 weeks with rasagiline 1 mg/day or 2 mg/day, or to
initiate treatment for 36 weeks with a placebo followed by 36 weeks
with rasagiline 1 mg/day or 2 mg/day.

The primary analysis included three hierarchical endpoints based on
total scores in the Unified Parkinson's Disease Rating Scale (UPDRS).
Azilect® 1 mg/day early-start met all endpoints of the primary
analysis: less deterioration in UPDRS score than placebo between
weeks 12 and 36; less worsening than delayed-start in UPDRS score in
comparing change between baseline and week 72 despite being on the
same medication for the last 9 months; and non-inferiority to
delayed-start in rate of deterioration between weeks 48 and 72. The
ADAGIO study also confirmed the positive symptomatic effect and
safety profile of Azilect®, in line with prior studies2.

About Azilect®
Azilect® (rasagiline) 1 mg tablets are indicated for the treatment of
the signs and symptoms of Parkinson's disease both as initial therapy
alone and to be added to levodopa later in the disease. Azilect® 1 mg
tablets are now available in 38 countries, including the U.S.,
Canada, Israel, Mexico and all of the European Union countries, where
it is marketed by Teva in collaboration with Lundbeck as part of a
long-term strategic alliance.

About Parkinson's disease
Parkinson's disease is an age-related degenerative disorder of the
brain. Symptoms can include tremor, stiffness, slowness of movement
and impaired balance. An estimated four million people worldwide
suffer from the disease, which usually affects people over the age of
60.

References
1.    Olanow CW et al. A double-blind delayed start trial of
rasagiline in Parkinson's disease. NEJM 2009
2.    Parkinson Study Group. A controlled trial of rasagiline in
early Parkinson's disease. Arch Neurol 2002;59:1937-1943


Lundbeck contacts


Investors:                   Media:

Jacob Tolstrup               Mads Kronborg
Director, IR & Communication Media Relations
+45 36 43 30 79              +45 36 43 28 51

Palle Holm Olesen            Kasper Riis
Head of Investor Relations   Media Relations
+45 36 43 24 26              +45 36 43 28 33

Magnus Thorstholm Jensen
Investor Relations Officer
+45 36 43 38 16



About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international
pharmaceutical company highly committed to improve the quality of
life for people suffering from central nervous system (CNS)
disorders. For this purpose Lundbeck is engaged in the research and
development, production, marketing and sale of pharmaceuticals across
the world, targeted at disorders like depression and anxiety,
schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson's
diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark,
and employs today over 5,500 people worldwide. Lundbeck is one of the
world's leading pharmaceutical companies working with CNS disorders.
In 2008, the company's revenue was DKK 11.3 billion (approximately
EUR 1.5 billion or USD 2.2 billion). For more information, please
visit www.lundbeck.com.